EBV-associated recurrent Hodgkin's disease after renal transplantation
| Autor: | Daniel C. Brennan, Katherine H. Flanagan |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male kidney transplant Nephrology Epstein-Barr Virus Infections Herpesvirus 4 Human medicine.medical_specialty recurrence medicine.medical_treatment Population Lymphoproliferative disorders Case Report Epstein–Barr virus Risk Factors immune system diseases hemic and lymphatic diseases Internal medicine Humans Medicine education Kidney transplantation Transplantation education.field_of_study business.industry Immunosuppression medicine.disease Hodgkin Disease Kidney Transplantation Lymphoproliferative Disorders Lymphoma surgical procedures operative post-transplant lymphoproliferative disease Immunology Kidney Failure Chronic Hodgkin's disease business Kidney disease |
| Zdroj: | Transplant International |
| ISSN: | 1432-2277 0934-0874 |
| DOI: | 10.1111/j.1432-2277.2006.00273.x |
| Popis: | Summary Hodgkin's disease is recognized as part of the spectrum of post-transplantation lymphoproliferative disorders (PTLD), although it is still an uncommon de novo malignancy in this population. Epstein–Barr virus (EBV) has been linked to both post-transplant non-Hodgkin's lymphomas and Hodgkin's disease. We report a case of recurrent Hodgkin's disease in a patient who received a renal transplant in childhood and later developed EBV-associated Hodgkin's disease with remission after chemotherapy until subsequent relapse 9 years later that was successfully treated. To our knowledge, this is the first report of recurrent Hodgkin's disease in a transplant recipient. We briefly discuss the pathogenesis of and risk factors for EBV-related PTLD, utility of EBV load surveillance, and the options for treatment of PTLD including immunosuppression reduction, antiviral therapy, anti-CD20 monoclonal antibodies, cytotoxic T cells, and the possible roles of interferon-α and rapamycin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text